北京茵诺医药科技有限公司成立于2016年，是北京专精特新企业。茵诺医药秉 承“茵起于医之仁，诺行于药之臻”的理念，致力于创新药的研发和生产。创始人 马茜博士拥有丰富的心内科临床经验，带领公司建立了自主知识产权的主动靶向纳 米药物递送技术平台。基于技术平台优势，围绕动脉粥样硬化、脑胶质瘤等临床亟 待满足的治疗领域，利用自有研发中心和生产基地，公司布局和推进多条产品管线 的研发和转化落地。 YN001已成功获得美国FDA和中国NMPA的临床试验批准，成 为全球首个进入临床试验的动脉粥样硬化靶向药，正在全球范围开展临床试验。

Founded in 2016, Beijing Inno Medicine Co., Ltd.(Inno Medicine) is a national high-tech enterprise. Inno Medicine is dedicated to the research, development, and manufacture of groundbreaking pharmaceuticals. Led by Dr. Qian Ma, the company has  pioneered  an  active  targeted  nano-drug  delivery  technology  platform  with proprietary intellectual property rights. Powered by this technological breakthrough, Inno Medicine focuses on addressing urgent unmet medical needs in conditions like atherosclerosis and glioma. YN001 has received IND approval from both US FDA and China NMPA, becoming the world's first targeted cardiovascular drug candidate to enter clinical trials.

地址：北京市海淀区西杉创意园C区9号楼3层
Building 9, Zone C, Xishan Innovation Industry Park, Haidian District, Beijing
86-010-82599080